Tango Therapeutics (TNGX) Proxy filing summary

Executive summary

• Significant progress in oncology drug development, including positive Phase 1/2 data for vopimetostat and initiation of new clinical trials in 2025, with pivotal studies planned for 2026.

• Raised $225 million in October 2025, extending operational runway into 2028 and supporting clinical advancement.

• Leadership transitions included Malte Peters, M.D. becoming CEO in January 2026 and Barbara Weber, M.D. moving to Executive Chairman.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class II Directors for terms ending in 2029, ratify PricewaterhouseCoopers LLP as auditor for 2026, and approve executive compensation on a non-binding basis.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 18, 2026, with additional requirements for director nominations.

Board of directors and corporate governance

• Board consists of eight members divided into three staggered classes, with annual elections for one class.

• Majority of directors are independent; board committees include audit, compensation, and nominating/governance.

• Board leadership is separated between Executive Chairman and CEO, with a lead independent director.

• Code of Conduct and robust director nomination process in place.